Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Acquires $47,600.00 in Stock

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Get Free Report) CEO Mihael Hristos Polymeropoulos acquired 10,000 shares of the business's stock in a transaction on Friday, February 28th. The stock was acquired at an average cost of $4.76 per share, for a total transaction of $47,600.00. Following the transaction, the chief executive officer now owns 2,361,730 shares of the company's stock, valued at approximately $11,241,834.80. The trade was a 0.43 % increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Mihael Hristos Polymeropoulos also recently made the following trade(s):

• On Tuesday, February 25th, Mihael Hristos Polymeropoulos acquired 10,000 shares of Vanda Pharmaceuticals stock. The stock was acquired at an average cost of $4.46 per share, for a total transaction of $44,600.00.

Vanda Pharmaceuticals Price Performance

Shares of NASDAQ VNDA traded up $0.09 during trading on Tuesday, reaching $4.81. 695,279 shares of the stock traded hands, compared to its average volume of 658,002. Vanda Pharmaceuticals Inc. has a 52-week low of $3.71 and a 52-week high of $6.75. The company has a 50-day moving average of $4.59 and a 200-day moving average of $4.79. The stock has a market capitalization of $280.50 million, a P/E ratio of -15.03 and a beta of 0.74.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.14) by $0.06. Vanda Pharmaceuticals had a negative return on equity of 3.49% and a negative net margin of 9.51%. The company had revenue of $53.19 million for the quarter, compared to analyst estimates of $51.00 million. Analysts expect that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current fiscal year.

Remove Ads

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. StockNews.com assumed coverage on Vanda Pharmaceuticals in a research report on Wednesday, February 5th. They set a "hold" rating on the stock. HC Wainwright upped their price target on Vanda Pharmaceuticals from $18.00 to $20.00 and gave the company a "buy" rating in a research report on Tuesday, February 18th.

Institutional Trading of Vanda Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in VNDA. China Universal Asset Management Co. Ltd. raised its stake in shares of Vanda Pharmaceuticals by 64.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company's stock valued at $53,000 after purchasing an additional 4,374 shares during the period. GSA Capital Partners LLP bought a new stake in shares of Vanda Pharmaceuticals during the 3rd quarter valued at $143,000. Empowered Funds LLC raised its stake in shares of Vanda Pharmaceuticals by 5.3% during the 3rd quarter. Empowered Funds LLC now owns 228,287 shares of the biopharmaceutical company's stock valued at $1,071,000 after purchasing an additional 11,524 shares during the period. Connor Clark & Lunn Investment Management Ltd. increased its stake in Vanda Pharmaceuticals by 7.7% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 780,933 shares of the biopharmaceutical company's stock worth $3,663,000 after acquiring an additional 55,567 shares during the last quarter. Finally, Intech Investment Management LLC bought a new position in Vanda Pharmaceuticals in the 3rd quarter worth about $84,000. 88.14% of the stock is currently owned by institutional investors.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.